No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
000963 Huadong Medicine
- 28.55
- -0.94-3.19%
Not Open Jun 27 15:00 CST
50.09BMarket Cap17.00P/E (TTM)
29.45High28.51Low106.81KlotVolume29.45Open29.49Pre Close308.39MTurnover0.61%Turnover Ratio17.65P/E (Static)1.75BShares45.8552wk High2.39P/B49.99BFloat Cap27.0252wk Low32.44Limit Up1.75BShs Float52.55Historical High26.54Limit Down3.19%Amplitude-3.03Historical Low0.58Dividend TTM28.87Avg Price59.45KlotAsk2.03%Div YieldTTM100Lot Size44.80KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Huadong Medicine - Hdm1002 Phase Ib Trial Shows Significant Weight Loss in 100Mg or Higher Dose Group
Express News | Huadong Medicine Co Ltd - Hdm1002 Significantly Reduces Postprandial Blood Glucose Levels
Express News | Huadong Medicine Announces Positive Phase I Results for Innovative Oral Small Molecule GLP-1 Receptor Agonist Hdm1002
Huadong Medicine (SZSE:000963) Shareholders Have Endured a 24% Loss From Investing in the Stock Three Years Ago
Investors can earn very close to the average market return by buying an index fund. But in any given year a good portion of stocks will fall short of that. Unfortunately for investors in Huadong Med
Huadong Medicine: Q1 2024 report (English version).
huadong medicine: 2023 annual report (English version)
Comments
Despite Huadong Medicine's strong earnings outlook and rapid growth, its low P/E ratio suggests investor skepticism about future earnings volatility. The company also shows 1 warning sign in investment analysis.
Fewer Investors Than Expected Jumping On Huadong Medicine Co., Ltd (SZSE:000963) 1
Despite the short-term decrease in returns on capital, the growth in revenue and capital employed for Huadong Medicine is seen as promising. If these growth trends continue, the stock could perform well in the future.
Despite falling EPS, rising share price hint at the market valuing future potential. Positive sentiments may be due to steady revenue growth, indicating investor anticipation. Dividend payments over last 3 years contributed significantly with a 68% total shareholder return.
Core point
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg